Detalhe da pesquisa
1.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194692
2.
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 - a Nordic Lymphoma Group study.
Haematologica
; 109(4): 1171-1183, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646663
3.
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors.
Haematologica
; 108(4): 1092-1104, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36519324
4.
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
Br J Haematol
; 197(6): 697-708, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35254660
5.
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
Hematol Oncol
; 40(1): 22-30, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34713465
6.
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.
Br J Haematol
; 193(3): 520-531, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33686666
7.
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma.
Eur J Nucl Med Mol Imaging
; 48(6): 1902-1914, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33196921
8.
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable.
Acta Oncol
; 60(11): 1481-1488, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34425735
9.
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
Br J Haematol
; 191(5): 796-805, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32748433
10.
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Haematologica
; 105(6): 1604-1612, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31537689
11.
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.
BMC Cancer
; 20(1): 1202, 2020 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33287742
12.
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Blood
; 129(6): 759-770, 2017 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28011673
13.
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood
; 130(17): 1903-1910, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28819011
14.
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003.
Eur J Nucl Med Mol Imaging
; 46(11): 2311-2321, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31309259
15.
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.
Br J Haematol
; 183(2): 225-234, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30080252
16.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
Blood
; 128(14): 1814-1820, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27354719
17.
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
Eur J Nucl Med Mol Imaging
; 45(7): 1233-1241, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29470615
18.
Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years.
Hematol Oncol
; 36(1): 217-223, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28393375
19.
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Biol Blood Marrow Transplant
; 23(3): 428-435, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28039078
20.
Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma.
Blood
; 125(1): 82-9, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25293773